AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$INBX

Lappe Mark purchased $2.6M of INBX (indirect holdings)

Lappe Mark (Chief Executive Officer) purchased 25,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $105.82 ($99.29–$112.28, $2.65M total) across 6 trades on 2026-09-08.

Original reporting
SEC EDGAR · Lappe Mark
Published Sep 8, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INBX
Bullish
medium confidence
Mentioned
$INBX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INBXBullishLow
01

Why it matters

The CEO's purchase adds credibility to the company's outlook and may attract short‑term buying interest.

02

Market read

Insider buying in a micro‑cap biotech can move the stock modestly, especially when disclosed on the same day.

03

What to watch

Potential upcoming clinical trial data or financing needs not disclosed could offset the positive signal.

Relevance 7/10Novelty 7/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions and are primary sources for new insider activity.

Company-level read

Ticker impact

$INBXBullishMedium confidence
Context

CEO Lappe Mark bought 25,000 shares for $2.65M, increasing his stake to 730,548 shares.

Expected impact

Potential modest price lift of 2‑4% over the next few trading days.

Evidence & confidence

A $2.6M buy by the CEO is material for a micro‑cap biotech and often precedes positive news flow, but the amount is modest relative to market cap.

Market effects

Sector

May boost sentiment in the biotech sector as insider buying is viewed positively.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • Person
    Lappe Mark

    Chief Executive Officer of Inhibrx Biosciences, Inc.

  • Company
    Inhibrx Biosciences, Inc.

    Biotech firm listed on Nasdaq under ticker INBX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INBX insider trading history →

Related articles

SEP 8
$INBXMedAI 8/10

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx Biosciences (INBX) reported positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs 26.5% for pembrolizumab alone, with 9.6-month median PFS. HPV+ patients saw even stronger results. The company plans to expand the trial and explore further applications. INBRX-106 is a hexavalent OX40 agonist.

prnewswire.com2 min
SEP 8
$INBXHighAI 8/10

Inhibrx stock jumps on positive cancer drug trial results

Inhibrx Biosciences (NASDAQ:INBX) shares rose 6% after reporting positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs. 26.5% for pembrolizumab alone. The study included 63 patients, with notable improvements in HPV-positive patients. The company plans to expand the trial and align with the FDA for a potential accelerated pathway.

investing.com2 min
AUG 13
$INBXMedAI 8/10

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.

prnewswire.com4 min
AUG 13
$INBXMed

Inhibrx Biosciences, Inc. (INBX): Results of Operations and Financial Condition

Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program

SEC EDGAR 8-K6 min
AUG 13
$INBXMedAI 8/10

FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results and said the FDA accepted its BLA for ozekibart (INBRX-109) in conventional chondrosarcoma, assigning a PDUFA goal date of April 14, 2027. The company also amended its Oxford Finance loan for up to $325.0 million. Q2 net loss was $36.7 million; cash was $219.5 million as of Aug. 6, 2026.

stocktitan.net4 min